Abstract:Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a rare and severe form of end-stage liver disease with high mortality; gut microbes are strongly associated with the development of this severe liver disease but the exact association is unclear. Artificial liver support systems (ALSS) are clinically important in prolonging the waiting time for liver transplantation and in aiding drug therapy to achieve remission. The aim of this study was to investigate the effect of ALSS on the abundance and diversity of microorganisms in the gut of HBV-ACLF patients. In this study, 109 stool samples were collected from patients with hepatitis B virus-associated acute chronic liver failure (HBV-ACLF) for 16S rRNA sequencing. Among them, 44 samples were from patients treated with ALSS therapy as an adjunct to standard medical treatment (SMT) and 65 were from patients receiving SMT only. Analysis of the sequencing results suggested that there were significant differences in the abundance and diversity of gut microbiota between the with-ALSS and without-ALSS groups (p < 0.05). The operational taxonomic units and Shannon indexes indicated that the diversity and abundance of the gut microbiome, while decreasing after the first ALSS treatment, gradually increased after an increase in the number of ALSS therapies. The overall proportion of HBV-ACLF patients with coinfection was 27.59%; the coinfection can reduce the abundance of the Bacteroidetes phylum in the microbiome significantly whereas Proteobacteria were highly enriched. After ALSS therapy, HBV-ACLF patients had a decrease in potentially harmful bacteria, an increase in potentially beneficial bacteria, an increase in the diversity of the intestinal microbiota, and the intestinal microecological disorders were corrected to a certain extent. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) levels, as well as the international normalized ratio (INR), showed a decreasing trend whereas plasminogen activity (PTA) increased and the condition of patients with HBV-ACLF progressed in a favorable direction. In addition, the abundance of Blautia and Coprococcus was negatively correlated with TBIL and INR, positively correlated with PTA, and positively correlated with disease recovery. Our study shows that ALSS can alter the composition of the gut microbiota and have an ameliorating effect on the gut microecological imbalance in HBV-ACLF patients. It is worth mentioning that Blautia and Coprococcus may have great potential as biomarkers.

Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis

Treatment of Hepatic Failure with Artificial Liver Support System.

ARTIFICIAL LIVER TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE: A PROPENSITY SCORE-MATCHED ANALYSIS

Artificial liver treatment improves survival in patients with hepatitis B virus‐related acute‐on‐chronic liver failure: A case‐control matched analysis

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Effect of Artificial Liver Support System on Patients with Severe Viral Hepatitis: A Study of Four Hundred Cases

Severe Hepatitis Treated with an Artificial Liver Support System

A Single-Center Experience of Non-Bioartificial Liver Support Systems among Chinese Patients with Liver Failure

The 90-Day Survival Threshold: A Pivotal Determinant of Long-Term Prognosis in HBV-ACLF Patients - Insights from a Prospective Longitudinal Cohort Study.

Predictive values of three indexes on short-term prognosis in patients with liver failure treated by artificial liver support system

A non-bioartificial liver support system combined with transplantation in HBV-related acute-on-chronic liver failure

A Prognostic Model for Hepatitis B Acute-on-chronic Liver Failure Patients Treated Using a Plasma Exchange-Centered Liver Support System.

Plasma Exchange-Based Non-bioartificial Liver Support System Improves the Short-Term Outcomes of Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure: A Multicenter Prospective Cohort Study

Effect of Artificial Liver Support Systems on Gut Microbiota in Patients with HBV-Related Acute-on-Chronic Liver Failure

Effects of Artificial Liver Support System on Patients With Acute or Chronic Liver Failure

Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis

Artificial Liver Support System Combined With Liver Transplantation In The Treatment Of Patients With Acute-On-Chronic Liver Failure

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.

Clinical Evaluation of Treatment with Artificial Liver Support System in Chronic Fulminant Viral Hepatitis

Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis

Artificial Liver Support System in China: a Review over the Last 30 Years.